Thursday, October 22, 2026 Published by AdvancedCare USA Inc.

TheraNews
Subscribe

Archive summary Clinical & research

Vanda Pharmaceuticals Q4 Earnings Call Highlights

Vanda Pharmaceuticals (NASDAQ:VNDA) highlighted strong growth for its lead product Fanapt and detailed several late-stage regulatory and clinical milestones during its fourth-quarter and full-year 2025 earnings call, while also reporting a sharply wider net loss driven largely by a one-time, non-cas

Summary of reporting by thelincolnianonline 1 min read Markdown

Vanda Pharmaceuticals Q4 Earnings Call Highlights

Originally reported by thelincolnianonline. Read more

Source: https://www.thelincolnianonline.com/2026/02/11/vanda-pharmaceuticals-q4-earnings-call-highlights.html

Original report

Vanda Pharmaceuticals Q4 Earnings Call Highlights
thelincolnianonline

About this article

  • Educational, not advice. Nothing here is medical, legal, billing or financial advice. Clinical decisions belong with a licensed clinician; coverage and legal questions belong with the payer, the statute or counsel. Prices and rates change; confirm them with the provider and the plan.
  • Corrections. If something on this page is wrong, send a correction with the source.

Topics: anxiety

Newsletter

The weekly digest

Weekly digest of US behavioral health policy and regulation, source-linked and practitioner-edited. Free; unsubscribe in one click.